Member Info for Doc.Daneeka

Good point Brand - but maybe they intend to target this in the secondary endpoints. The viral shedding data came from COPD ( as Fruits pointed out when I asked the question long ago in relation to Shionogi ) but if all of our patients are in ICU it's not so obviously a win as it is for early infection treatments.

What we're waiting for

TWO trials.

First for Viral Respiratory patients in ICU - multi viral Flu, RSV, Covid, COPD, etc

Second for Ventilated patients

What they have to do

1. Patient ID using previous data TICK

2. Patient ID using genomics QUESTION MARK

3. Patient ID and dosage etc for Ventilator cohort ( multi arm trial )

4. Site Approval

5. Regulatory Approval

Auto-abs assays could be a hold-up - hope not as they will only identify 10.3% of our patients. Reg approval could be a hold up - but shouldn't be as such small trials and huge safety data in place. The original data was analyzed months and months ago - so that shouldn't be a hold up. Sites - no probs except maybe the US.

I predict FPD on May 18th

as i said - i wasn't here before aug 2020 but i certainly take issue with the idea that there were regular postings. they put up news when they had it and almost nothing from the time they announced a trial until the moment it concluded. we knew nothing of the design of sprinter and once it started we got nothing except fpd and then lpd. they didn't even tell us where they were trialing. it was a major event on the bb when someone confirmed a country or hospital. i mean they really could have easily released that info before the trial ended.

they're just **** at it - which is fine when you're winning but disastrous when the share is in the toilet

thanks ghia i've only been here since early august 2020 - but it seems to me they've only ever posted when they've had tangible news to report. in the period from the end of sg016 to the sporinter crash things were happening regularly. there were still long periods of nothing - remember the long wait for the home traial to fill ... but the vacuum was filled with news - peer reviews - inclusion on activ-2 - sprinter starting - appearances at conferences. we're looking at a 2 year timeline to this point and in the first year of this they were very busy with post hoc and conferences plus the whole rick bright circus in the states.

so - they could have given us more since the agm or interims - but univeral data can only come from southampton uni - and we've had a dribble of that - and the other main activity is working with casanovalabs et al on the extra tests they'll use for patient id and that's secret squirrel - and getting the regulatory framework lined up which is also not to be discussed publicly

i'm sounding like td - but i don't necessarily think that they could have posted weigh points towards the trial commencement - which is very different to engaging the shareholders in other ways. we're ****ed off because they've said nothing and that is pathetic - but if the trials are this complicated then we're still well inside the window thay gave us in september and there's still imo no reason to expect them to be late. .

Gunto - it's possible they'll miss H1 - but as and your pals have been telling us - we're only just 5 weeks in and that's still true. It's pointless to speculate further when we have absolutely zero to tell us if they're on track or not.

Ghia needs now to explain why he's posting this now - and what his prediction is based on.

Tommy

a) we know what subtle means

b) Ghia's post was anything but.

We've made some progress in the last couple of days.

1. Mani has her answer to the question about SNG availabilty

2. MrC has finally got through and had a nice heart to heart with Michelle ( PA to the Directors) .

Not being facetious at all - but I hope on those points at least they feel some comfort.

The rest of it will continue as usual - we'll wake at 6 to our favourite tune and wait for Punxsutawney Phil to tell us how long the Synairgen winter will last.

https://youtu.be/OyBSrBqogPY?si=tr9wEAwLwgJ1EpNb

Nice post Tommy ...... Nice post Gunto ....... Meanwhile on planet Earth

We all know traders are nothing to do with 4.5p. In order to trade you do occasionally need the sp to shift upwards. That hasn't happened for a year. And it's nothing to do with posters who ask challenging questions or refuse to accept the daily regurgitation of partially relevant industry studies in Ifns or - lately - Auto-abs. ( remember 10.3% of patients in ICU had Auto-abs for Ifns - they fared exactly the same as ther main patient population )

A joined-up & mature approach to comms would not change any of the fundamentals for LTHs - who are stuck, happily or unhappily on this desert island - but might go some way to reassuring any new pis in particular that their investment wasn't a mistake. And we'd all be reassured if there was an occasional glimpse of the raft-building party hard at work on the shore or building the rescue beacon.

"Meanwhile, the price will continue to drift downwards. "

Not like you to express such negativity Gunto. I mean - why should the price continue to drift downwards ? This should be a period of stasis - TFG secure - LTHs on board (or stuck). A clear outline of the way forward. Low trading volume. Instead we have atrophy, slide, and drift.

The sp is the most literal indicator of investor confidence. Surely with that disastrous day in '22 so far behind us and with so much supportive evidence deliver in the interim period and new trials almost upon us - we should at least be trading at the 9.5p that greeted the interim report.

I think they were probably upset at the robustness of the AGM questioning when Doc83 - in particular - asked the most difficult questions compiled from suggestions on here. It seemed in the immediate aftermath that the main thrust went home but in actuality it drove them into the bunker. The proactive interview was RM's only one of the whole year and it was pathetic.

Mani "Yes, but does that include a delay? "

The money might run out Mani but if they've made new juice since September that's unlikely to go sour in the few extra months we might be waiting.

Mani - Hopefully Td's reposting of the Interim report yesterday put your mind at ease on the oft-repeated question about whether they have the drug and whether it's in date. It seems they are making new SNG001 and placebo, which makes sense given the timescale since the last trial and the fact they require only a small quantity.

"“The Company’s cash resources are sufficient to cover its plans to design and

establish data from an observational study and two investigator-led/Synairgen-

sponsored Phase 2 clinical trials, including manufacture of active and placebo

for use in these trials”

Nice work pmjh.

Started at £1 - went to £2 - then £5 and a villa in Barbados and now topping out at £10.

It's the weekend i guess and people are allowed to indulge those old fantasies. Remember though that whatever it gets to after the P2s has to be divided by either the cash cost of the P3 that will follow - or a slicing of future profits. Best short term scenario - for all of us - will be a quick accepted offer, with someone else worrying about how to get it to market. Better long term scenario is Synairgen remaining intact and growing fat on licensing revenue. I can't see the characters in charge managing anything that clever though so I'll join everyone except the die-hards and hope for £1 to £2 - and that price at least lift my hat to Al as Mrs D and I waft past his Barbadian summer retreat on the morning breeze

If i stay here just a little bit longer....

Which update was that TP ?

Thanks Jint - makes sense

Everything you need to know about the assay science is in the trial link I posted earlier. It's a specific study for auto-abs and Ifns and it suggests to me that auto-ab identification will be the least significant or useful contributor to the protocols. 10.3 % of 927 patients had em and they fared exactly the same across a range of metrics as the non auto-ab population.

Even if there are other studies suggesting more severe outcomes they are not as clean in terms of data and it seems that in critically ill patients the other factors such as age and co-morbities completely swamp the negative effect of auto-abs.

They actually conclude the auto-abs may play a more significant role in outcomes before ICU

Spacman - yep and they must have come here and committed to UNIVERSAL for the connection with Synairgen.